Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (SNDX) had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $34.00. They now have a "buy" rating on the stock.
Syndax Pharmaceuticals (SNDX) had its price target lowered by Mizuho from $45.00 to $43.00. They now have an "outperform" rating on the stock.
Syndax Pharmaceuticals (SNDX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $40.00 price target on the stock, down from $48.00.